6 completed. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 2 | Completed 2 |
Follow this drug Literature Review of PF-06835919 trials Research Report on PF-06835919
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Multiple Oral Doses of PF-06835919 in Healthy Adult Japanese Participants PF-06835919, Placebo - Healthy | Phase 1 | Completed | Pfizer | 8 | 2020-11-24 | 2022-07-21 |
| A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENT PF-06835919 25 mg - Hepatic Impairment, Healthy Participants | Phase 1 | Completed | Pfizer | 23 | 2020-01-21 | 2024-02-16 |
| A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus Placebo, PF-06835919 - Non-alcoholic Steatohepatitis | Phase 2 | Completed | Pfizer | 164 | 2019-07-18 | 2022-05-11 |
| 6-week Safety and PD Study in Adults With NAFLD Placebo, PF-06835919 Low Dose, PF-06835919 High Dose - Non-alcoholic Fatty Liver Disease | Phase 2 | Completed | Pfizer | 53 | 2017-09-27 | 2019-04-04 |
| Multiple Ascending Dose and DDI Study Placebo, PF-06835919, atorvastatin - Healthy Volunteers | Phase 1 | Completed | Pfizer | 62 | 2017-01-01 | 2017-09-06 |
| Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects PF-06835919, Placebo - Non-alcoholic Fatty Liver Disease | Phase 1 | Completed | Pfizer | 16 | 2016-10-01 | 2017-12-15 |
Non-alcoholic Fatty Liver Disease (6) · Diabetes Mellitus, Type 2 (1)
Pfizer (6)
Belgium (3) · United States (3) · Canada (1) · Czechia (1) · Slovakia (1)
2016 (1), 2019 (1)